Global Orthopedic Bone Cement Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Orthopedic Bone Cement Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Orthopedic bone cements can be defined as biomaterials obtained by mixing a powder phase and a liquid phase, which can be molded and implanted as a paste and have the ability to set once implanted within the body. They are widely used in different applications of orthopedic surgery. Orthopedic bone cement is being used for in arthroplasty procedures for over four decades for the purpose of total joint replacement prosthesis to periprosthetic bone. Orthopedic bone cement helps support and anchor artificial joints and fractured bones. It works by filling the empty space between the bone and an implant, which anchors the joint. This in turn provides stability and elasticity to the joints. All in all, orthopedic bone cement helps to support and strengthen prosthetic joints and broken bones. The growing number of orthopedic surgeries in the world is expected to increase the demand for cement.

Market Overview:

The latest research study on the global Orthopedic Bone Cement market finds that the global Orthopedic Bone Cement market reached a value of USD 1073.57 million in 2022. It’s expected that the market will achieve USD 940.49 million by 2028, exhibiting a CAGR of -2.18% during the forecast period.

Orthopedic Bone Cement Market Trends

A growing number of joint replacement surgeries fueled by an aging population and rising trauma cases are anticipated to raise demand for orthopedic bone cement. This represents a good opportunity for orthopedic bone cement manufacturers globally.

In addition, the increasing number of products launched and industry consolidation is expected to strengthen the market over the forecast period. Growing investments in R&D activities and expanding applications are expected to be key parameters for maintaining a competitive edge, with frequent partnerships being undertaken as an attempt to diversify end-use portfolios and gain market share. For instance, in June 2015, Zimmer Holdings, Inc. completed the acquisition of Biomet, which in turn is anticipated to increase revenue consolidation and strengthen the companys distribution channel.

Apart from this, advancements in end-use technology and the introduction of new applications are anticipated to increase demand. For instance, Stryker introduced Simplex bone cement that is claimed to undergo less deformation post usage. Manufacturers have also introduced antibiotic-loaded cement that decreases the chances of post-surgical infections, especially in the case of total joint arthroplasty. Advancements in end-use technology are expected to increase the adoption of orthopedic bone cement among physicians.

Orthopedic Bone Cement Opportunities and Drivers

The increasing number of orthopedic surgeries globally is expected to boost demand for the cement in near future. As per the Australian Society of Orthopedic Surgeons, the number of musculoskeletal surgeries increased by 18% between 2007 and 2011 and is expected to witness continuous growth, which in turn is expected to create growth opportunities for the manufacturers.

Orthopedic Bone Cement Challenges

Orthopedic Bone cement is a material commonly used in joint replacement surgeries and may fragment, causing prosthetics to loosen. Bone cement may be linked to serious complications like the loosening of hip and knee replacements, bone cement implantation syndrome, pulmonary embolism, and cardiac arrest. Bone cement may also cause a condition known as bone cement implantation syndrome (BCIS). BCIS is a serious medical condition in which fat, bone marrow, and cement may leak into the bloodstream. When this occurs, patients may suffer from blood clots, pulmonary embolism, cardiac arrest, and other serious adverse events.

Hypotensive episodes and cardiac arrest have been reported during cement insertion. Pressurization and thorough cleaning of the bone with the expulsion of bone marrow has been associated with the occurrence of pulmonary embolisms, and this risk has been found to be increased in patients with highly osteoporotic bone and patients diagnosed with a femoral neck fracture. Reaming of the marrow cavity can have similar effects on mean arterial pressure as the introduction of bone cement. Marrow cavities should be vented when the cement is introduced digitally. The premature insertion of bone cement may lead to a drop in blood pressure, which has been linked to the availability of methyl methacrylate at the surface of the product, although this has not been proven. This drop in blood pressure, on top of hypotension induced either accidentally or intentionally, can lead to cardiac arrhythmias or to an ischaemic myocardium. However, according to a report, the possible risk of death associated with the use of cemented implants is confined to early postoperative and perioperative periods.

Factors such as porosity, viscosity, radio pacifiers, sterilization, biocompatibility, and the presence of antibiotic additives and mixing methods are known to affect the clinical performance of bone cements. Adverse effects of bone cement such as cardiopulmonary complications, hypersensitivity to components such as benzoyl peroxide, and the presence of methylmethacrylate prove to be a major drawback to the use of bone cements. Thus, owing to these factors the orthopedic bone cement market is likely to create growth opportunities in the forecast period.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

Stryker, Zimmer Biomet, DePuy Synthes, Smith & Nephew, and Heraeus Group are the five key players in the global Orthopedic Bone Cement market. These companies have shown consistent growth in revenue, larger volumes of sales, and a prominent presence in terms of share in the global Orthopedic Bone Cement market in the past 5 years.

Stryker is one of the world's leading medical technology companies and, together with customers, Stryker is driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world.

Zimmer Biomet Holdings, Inc. designs, develops, manufactures, and markets medical equipment. The Company offers orthopedic, dental, and spinal reconstructive implants, as well as bone cement and related surgical products. Zimmer Biomets innovations help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Alongside some of the world's top healthcare professionals, Zimmer Biomet helps deliver new possibilities to patients. Zimmer Biomet Holdings serves patients worldwide.

Segmentation Overview:

Among different product types, Low Viscosity Bone Cements segment is anticipated to contribute the largest market share in 2027.

Orthopedic bone cements differ in terms of their initial viscosity. There are high, medium and low-viscosity bone cements. Viscosity refers to the consistency and low-viscosity bone cement has a very liquid consistency after mixing whereas high-viscosity bone cement has a solid consistency. The change in the viscosity from an initially liquid state until the bone cement dough is set can be affected by the mixing technique, the temperature and/or the humidity. Low-viscosity bone cements have a long-lasting liquid, or mixing phase, which makes for a short working phase. As a consequence, the application of low-viscosity cements requires strict adherence to application times.

Medium viscosity cements are both low and high in viscosity, depending on the time at which the cement is delivered. Medium viscosity cements are considered to be dual-phase cements. They begin in a low viscosity state while being mixed, which allows for the easy and homogenous mixing of the powder and the liquid.

High-viscosity bone cements have a short mixing phase and lose their stickiness quickly. This makes for a longer working phase, giving the surgeon more time for application. Ideal viscosity will be high enough to avoid any cement mixing with blood or fat/bony material from the implantation region yet low enough to penetrate the bone adequately.

Antibiotic bone cement releases the antibiotic agent into the surrounding tissue. Antibiotic bone cements may offer early protection against the formation of bacterial biofilm after joint arthroplasty. The antibiotic bone cement may be used to either treat an infection following surgery or to try to prophylactically prevent an infection at the time of surgery.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Orthopedic Bone Cement market covered in Chapter 3:

Zimmer Biomet
Tecres
DePuy Synthes
Smith & Nephew
Medacta
Heraeus Group
Stryker

In Chapter 4 and Chapter 14.2, on the basis of types, the Orthopedic Bone Cement market from 2018 to 2029 is primarily split into:

Low Viscosity Bone Cements
Medium Viscosity Bone Cements
High Viscosity Bone Cements
Antibiotic Bone Cements

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Orthopedic Bone Cement market from 2018 to 2029 covers:

Hospitals
Ambulatory Surgical Centers (ASCs)
Specialty Clinics
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)